A research paper can disclose funding for the work and separate financial relationships for its authors. For example, our guide to the semaglutide cost model for MASH explains how assumptions and sponsorship fit together. Read the funding statement alongside the methods and results.
What a review disclosed
A 2025 systematic review included a sample of 60,307 participants from 56 obesity medication trials [1]. Of the 60 comparisons, 14 involved semaglutide and six involved tirzepatide. Some trials contributed multiple comparisons. The competing interests section describes author ties including advisory fees, speaking fees and research grants. Those disclosures do not identify a sponsor for every trial in the review.
What manufacturers supported in two economic models
Two authors of a US semaglutide MASH model worked for Novo Nordisk, and the third worked for a company Novo contracted [2]. The model estimated $19,911 per additional quality-adjusted life year compared with standard care. That is a projected cost-effectiveness ratio for a defined patient group.
Another analysis used a clinical trial to project costs beyond the period that researchers observed [3]. The tirzepatide lifetime cost model includes authors affiliated with Eli Lilly. A lifetime projection depends on drug prices, how long people stay on treatment and how the model estimates later complications.